Compare FTAI Aviation Ltd (FTAI) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Medpace Holdings Inc — how do they compare? FTAI Aviation Ltd trades at $169.97 (market cap $17.57B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: FTAI Aviation Ltd and Medpace Holdings Inc are close in size by market cap, and FTAI Aviation Ltd pays a 1.17% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 23 Days and Medpace Holdings Inc for 14 Days on average.
| FTAI | MEDP | |
|---|---|---|
Market Cap | $17.57B | $16.82B |
Volume | 1,905,014 | 223,093 |
Sector | Industrials | Health |
52-Week High | $310.04 | $630.19 |
52-Week Low | $152.80 | $393.42 |
Typical Hold Time | 23 Days | 14 Days |
Enterprise Value | $20.69B | $16.44B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $171.06, down 2.16% amid a bearish technical signal, with support at $169 and resistance at $173. The company reported strong 2025 revenue of $2.51B and net income of $501M, though recent quarters have missed EPS estimates. Recent developments include a $500M share buyback program and a 5-year Asia-Pacific maintenance deal with GMF, signaling strategic growth initiatives.
The outlook is mixed: robust analyst consensus (100% buy ratings, $321.25 price target) and shareholder-friendly actions support upside, but consecutive earnings misses, negative operating cash flow, and high valuation ratios (P/E 37.35) pose risks. Investors should weigh growth in aerospace segments against execution challenges and macroeconomic headwinds.
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
